Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

335.28 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,203
Open	335.28
Bid (Size)	327.31 (100)
Ask (Size)	383.00 (100)
Prev. Close	335.28
Today's Range	335.28 - 335.28
52wk Range	26.70 - 349.32
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Performance

YTD	+17.1%	+17.1%
1 Month	+7.6%	+7.6%
3 Month	+75.7%	+75.7%
6 Month	+614.3%	+614.3%
1 Year	+402.6%	+402.6%

More News

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory Milestones ↗

February 19, 2026

Via Chartmill

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock ↗

February 20, 2026

Via Stocktwits

Praxis Medicines Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Via The Motley Fool

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

February 19, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Via The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

Via The Motley Fool

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

February 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 12, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

January 08, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Why Praxis Precision Medicines Stock Popped Today ↗

December 29, 2025

Via The Motley Fool

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗

December 29, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗

December 29, 2025

Via Stocktwits

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 335.28

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 02/20/26 04:00 PM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 14.99B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 15B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.